Patents by Inventor Richard W. Childs
Richard W. Childs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024479Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin-2 receptor beta intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.Type: ApplicationFiled: October 3, 2023Publication date: January 25, 2024Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan
-
Publication number: 20240009236Abstract: Modified NK cells with reduced expression of CCR5 are provided. Methods of treating a subject with cancer with the modified NK cells are also provided. In some examples, the modified NK cells also have reduced expression of one or more of CCR1, CXCR6, and CD38, increased expression of one or more of CXCR4, CCR7, and CXCR3, and/or express a chimeric antigen receptor.Type: ApplicationFiled: November 3, 2021Publication date: January 11, 2024Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, Emily R. Levy, Joseph Clara
-
Patent number: 11779603Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an ? chain (such as SEQ ID NO: 2) and a ? chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR ? and/or ? chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR ? chain and the TCR ? chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR ? chain and the TCR ? chain, and administering a composition comprising the modified T cells to the subject.Type: GrantFiled: June 30, 2017Date of Patent: October 10, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of ChicagoInventors: Richard W. Childs, Michael I. Nishimura, Elena A. Cherkasova
-
Publication number: 20230089654Abstract: Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some embodiments, the NK cells or T cells express a thrombopoietin receptor or an erythropoietin receptor. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.Type: ApplicationFiled: August 23, 2022Publication date: March 23, 2023Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan, Chantiya Chanswangphuwana
-
Publication number: 20220228117Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: ApplicationFiled: March 7, 2022Publication date: July 21, 2022Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan
-
Patent number: 11293010Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: GrantFiled: November 1, 2017Date of Patent: April 5, 2022Assignee: The United States of America, as represented by the Secretary, Department and of Health and Human ServicesInventors: Richard W. Childs, David S. J. Allan
-
Publication number: 20200392457Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: ApplicationFiled: November 1, 2018Publication date: December 17, 2020Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, David S.J. Allan
-
Publication number: 20200360436Abstract: Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.Type: ApplicationFiled: August 5, 2020Publication date: November 19, 2020Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Richard W. Childs, Mattias C.V. Carlsten
-
Patent number: 10813952Abstract: Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.Type: GrantFiled: November 13, 2015Date of Patent: October 27, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard W. Childs, Mattias C.V. Carlsten
-
Publication number: 20190231821Abstract: Disclosed herein are T cell receptors (TCRs) capable of binding an antigen expressed by renal cell carcinoma cells. In some examples, the TCRs include an ? chain (such as SEQ ID NO: 2) and a ? chain (such as SEQ ID NO: 3). Also disclosed herein are vectors including nucleic acids encoding the disclosed TCR ? and/or ? chains. Further disclosed are modified T cells expressing the TCRs. In some examples, the modified T cells are prepared by transducing T cells with a vector including nucleic acids encoding the TCR ? chain and the TCR ? chain. In some embodiments, methods include treating a subject with RCC, by obtaining a population of T cells, transducing the population of T cells with a vector including a nucleic acids encoding the TCR ? chain and the TCR ? chain, and administering a composition comprising the modified T cells to the subject.Type: ApplicationFiled: June 30, 2017Publication date: August 1, 2019Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Loyola University of ChicagoInventors: Richard W. Childs, Michael I. Nishimura, Elena A. Cherkasova
-
Publication number: 20180325951Abstract: Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.Type: ApplicationFiled: November 13, 2015Publication date: November 15, 2018Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard W. Childs, Mattias C.V. Carlsten
-
Patent number: 10106620Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.Type: GrantFiled: June 15, 2015Date of Patent: October 23, 2018Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Janssen Biotech, Inc.Inventors: Richard W. Childs, Maria Berg, Luis Espinoza Calderon, Kate Sasser, Ricardo Attar
-
Publication number: 20180208669Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.Type: ApplicationFiled: June 15, 2015Publication date: July 26, 2018Applicants: The United States of America, as represented by th e Secretary, Dept. of Health and Human Services, Janssen Biotech, Inc.Inventors: Richard W. Childs, Maria Berg, Luis Espinoza Calderon, Kate Sasser, Ricardo Attar
-
Publication number: 20180057795Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.Type: ApplicationFiled: November 1, 2017Publication date: March 1, 2018Inventors: Richard W. Childs, David S.J. Allan
-
Patent number: 9296500Abstract: Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.Type: GrantFiled: June 16, 2014Date of Patent: March 29, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services of the Office of Technology Transfer, National Institutes of HealthInventors: Richard W. Childs, Herb Cullis, Sumithira Vasu, Phillippe Jean Broussard, Kevin Douglas Clark, Eric Kelsey Harting
-
Publication number: 20140290183Abstract: Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Richard W. Childs, Herb Cullis, Sumithira Vasu, Phillippe Jean Broussard, Kevin Douglas Clark, Eric Kelsey Harting
-
Patent number: 8790597Abstract: Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.Type: GrantFiled: May 4, 2010Date of Patent: July 29, 2014Assignee: The United States of Americas, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard W. Childs, Herb Cullis, Sumithira Vasu, Phillippe Jean Broussard, Kevin Douglas Clark, Eric Kelsey Harting
-
Publication number: 20120064603Abstract: Methods and apparatus for selectively accessing a portion of a sterile cryopreserved sample are disclosed. The apparatus may include a container configured to receive the cryopreserved sample and having a first portion and a second portion, a heat sink chamber surrounding the first portion of the container, and a heat source adjacent to the second portion of the container. The chamber may be configured to maintain a non-accessed portion of the sample in a cryopreserved state. The heat source may be configured to separating an accessed portion of the sample from the non-accessed portion of the sample while maintaining the viability of the accessed portion while the non-accessed portion is maintained in the cryopreserved state.Type: ApplicationFiled: May 4, 2010Publication date: March 15, 2012Applicant: American Fluoroseal CorporationInventors: Richard W. Childs, Herb Cullis, Sumithira Vasu, Phillippe Jean Broussard, Kevin Douglas Clark, Eric Kelsey Harting